854 related articles for article (PubMed ID: 11965039)
1. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
Ciancio G; Burke GW; Suzart K; Roth D; Kupin W; Rosen A; Olson L; Esquenazi V; Miller J
Transplantation; 2002 Apr; 73(7):1100-6. PubMed ID: 11965039
[TBL] [Abstract][Full Text] [Related]
2. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
[TBL] [Abstract][Full Text] [Related]
3. Daclizumab induction as an immunosuppressive regimen for renal transplant recipients from non-heart-beating donors.
Sánchez-Fructuoso AI; Prats D; Marques M; Ridao N; Conesa J; García Mena M; Torrente J; Barrientos A
Transplant Proc; 2003 Aug; 35(5):1689-90. PubMed ID: 12962759
[TBL] [Abstract][Full Text] [Related]
4. Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients.
Bruce DS; Sollinger HW; Humar A; Sutherland DE; Light JA; Kaufman DB; Alloway RR; Lo A; Stratta RJ
Transplantation; 2001 Nov; 72(10):1637-43. PubMed ID: 11726823
[TBL] [Abstract][Full Text] [Related]
5. Daclizumab induction for primary kidney transplant recipients using tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.
Ciancio G; Miller A; Burke GW; Gharagozloo H; Rosen A; Roth D; Kupin W; Pinna A; Cespedes M; Esquenazi V; Miller J
Transplant Proc; 2001; 33(1-2):1013-4. PubMed ID: 11267169
[No Abstract] [Full Text] [Related]
6. Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.
Ciancio G; Burke GW; Suzart K; Vaidya A; Roth D; Kupin W; Mattiazzi A; Rosen A; Esquenazi V; Miller J
Transplant Proc; 2003 Mar; 35(2):873-4. PubMed ID: 12644172
[No Abstract] [Full Text] [Related]
7. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring.
Ciancio G; Burke GW; Gaynor JJ; Carreno MR; Cirocco RE; Mathew JM; Mattiazzi A; Cordovilla T; Roth D; Kupin W; Rosen A; Esquenazi V; Tzakis AG; Miller J
Transplantation; 2005 Aug; 80(4):457-65. PubMed ID: 16123718
[TBL] [Abstract][Full Text] [Related]
8. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis.
Stratta RJ; Alloway RR; Hodge E; Lo A;
Clin Transplant; 2002 Feb; 16(1):60-8. PubMed ID: 11982617
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: a multicenter, prospective, pilot trial.
Abramowicz D; Vanrenterghem Y; Squifflet JP; Kuypers D; Mourad M; Meurisse M; Wissing M
Clin Transplant; 2005 Aug; 19(4):475-82. PubMed ID: 16008591
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
[TBL] [Abstract][Full Text] [Related]
11. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients.
Kuypers DR; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
Clin Transplant; 2003 Jun; 17(3):234-41. PubMed ID: 12780674
[TBL] [Abstract][Full Text] [Related]
12. The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients.
Eckhoff DE; McGuire B; Sellers M; Contreras J; Frenette L; Young C; Hudson S; Bynon JS
Transplantation; 2000 May; 69(9):1867-72. PubMed ID: 10830224
[TBL] [Abstract][Full Text] [Related]
13. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation.
Sarwal MM; Vidhun JR; Alexander SR; Satterwhite T; Millan M; Salvatierra O
Transplantation; 2003 Nov; 76(9):1331-9. PubMed ID: 14627912
[TBL] [Abstract][Full Text] [Related]
14. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
Asberg A; Midtvedt K; Line PD; Narverud J; Holdaas H; Jenssen T; Reisaeter AV; Johnsen LF; Fauchald P; Hartmann A
Transplantation; 2006 Jul; 82(1):62-8. PubMed ID: 16861943
[TBL] [Abstract][Full Text] [Related]
15. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation.
Hirose R; Roberts JP; Quan D; Osorio RW; Freise C; Ascher NL; Stock PG
Transplantation; 2000 Jan; 69(2):307-11. PubMed ID: 10670644
[TBL] [Abstract][Full Text] [Related]
16. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
[TBL] [Abstract][Full Text] [Related]
17. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation.
Sarwal MM; Yorgin PD; Alexander S; Millan MT; Belson A; Belanger N; Granucci L; Major C; Costaglio C; Sanchez J; Orlandi P; Salvatierra O
Transplantation; 2001 Jul; 72(1):13-21. PubMed ID: 11468528
[TBL] [Abstract][Full Text] [Related]
18. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function.
Emre S; Gondolesi G; Polat K; Ben-Haim M; Artis T; Fishbein TM; Sheiner PA; Kim-Schluger L; Schwartz ME; Miller CM
Liver Transpl; 2001 Mar; 7(3):220-5. PubMed ID: 11244163
[TBL] [Abstract][Full Text] [Related]
19. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation.
Ahsan N; Holman MJ; Jarowenko MV; Razzaque MS; Yang HC
Am J Transplant; 2002 Jul; 2(6):568-73. PubMed ID: 12118902
[TBL] [Abstract][Full Text] [Related]
20. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
